OCUL
OCULAR THERAPEUTIX, INC
+0.44 (+4.41%)10.31USD740K成交股數2.3B市值–本益比(近四季)43.5股價營收比+0.1%營收年增(近四季)2026-11-04下次財報
內部人交易 SEC Form 4 · 董事、高階主管與持股 10% 以上股東 · 交易後兩個營業日內申報
買賣點與股價近一年
● 公開市場買進 · ● 公開市場賣出 · 空心 = 10b5-1 預設計畫(事先排程,不代表當下看法)。近一年,只畫 P / S 兩種代碼。
統計
| 近 90 天 買進筆數 · 金額 · 人數 | 0 · 0.00 · 0 |
|---|---|
| 近 90 天 賣出筆數 · 金額 · 人數 | 5 · 333K · 5 |
| 其中 10b5-1 計畫賣出 | 4 筆 |
| 近 180 天 買進 · 賣出金額 | 0.00 · 694K |
| 近 180 天 淨額 | −694K |
公開市場買進(P)是內部人自掏腰包,通常比賣出更有資訊含量 —— 賣出的理由很多(繳稅、分散、買房),買進的理由只有一個。
10b5-1 是事先排定的交易計畫,執行時點不反映當下看法。獲配股票(A)、繳稅扣股(F)、選擇權執行(M)是薪酬流程,不是意見。
| 交易日 | 申報日 | 申報人 | 職稱 | 代碼 | 股數 | 價格 | 金額 | 交易後持股 | 原件 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-31 | 09-02 | Notman Donald | Chief Operating Officer | S 公開市場賣出 | 1.1K | 10.24 | 11K | 367K | SEC |
| 2026-08-25 | 08-26 | Dugel Pravin | See Remarks | G 贈與 | 50.1K | – | – | 745K | SEC |
| 2026-08-25 | 08-26 | Dugel Pravin | See Remarks | G 贈與 | 50.1K | – | – | 0 | SEC |
| 2026-08-24 | 08-26 | Kaiser Peter | Chief Development Officer | S 公開市場賣出(10b5-1) | 3.0K | 10.77 | 33K | 264K | SEC |
| 2026-08-24 | 08-26 | Dugel Pravin | See Remarks | S 公開市場賣出(10b5-1) | 21.6K | 10.77 | 233K | 2.5M | SEC |
| 2026-08-24 | 08-26 | Heier Jeffrey S. | Chief Scientific Officer | S 公開市場賣出(10b5-1) | 3.3K | 10.78 | 36K | 318K | SEC |
| 2026-08-24 | 08-26 | Nayak Sanjay | Chief Strategy Officer | S 公開市場賣出(10b5-1) | 1.9K | 10.78 | 20K | 327K | SEC |
| 2026-06-16 | 06-18 | Dugel Pravin | See Remarks | G 贈與 | 50.1K | – | – | 50.1K | SEC |
| 2026-06-16 | 06-18 | Dugel Pravin | See Remarks | G 贈與 | 50.1K | – | – | 2.5M | SEC |
| 2026-06-10 | 06-12 | Graves Adrienne L | Director | A 獲配股票 | 14.0K | – | – | 64.0K | SEC |
| 2026-06-10 | 06-12 | LINDSTROM RICHARD L MD | Director | A 獲配股票 | 14.0K | – | – | 261K | SEC |
| 2026-06-10 | 06-12 | Hong Seung Suh | Director | A 獲配股票 | 14.0K | – | – | 60.9K | SEC |
| 2026-06-10 | 06-12 | RAINES MERILEE | Director | A 獲配股票 | 14.0K | – | – | 60.9K | SEC |
| 2026-06-10 | 06-12 | Robins Jason Shand | Chief Financial Officer | A 獲配股票 | 15.4K | – | – | 68.1K | SEC |
| 2026-06-10 | 06-12 | Warden Charles M | Director | A 獲配股票 | 14.0K | – | – | 100K | SEC |
| 2026-06-10 | 06-12 | Williams Leslie J. | Director | A 獲配股票 | 14.0K | – | – | 65.4K | SEC |
| 2026-06-03 | 06-05 | Waheed Nadia | Chief Medical Officer | S 公開市場賣出(10b5-1) | 14.8K | 8.27 | 123K | 300K | SEC |
| 2026-05-28 | 05-28 | Dugel Pravin | See Remarks | G 贈與 | 395K | – | – | 695K | SEC |
| 2026-05-28 | 05-28 | Dugel Pravin | See Remarks | G 贈與 | 395K | – | – | 0 | SEC |
| 2026-05-26 | 05-28 | Nayak Sanjay | Chief Strategy Officer | S 公開市場賣出(10b5-1) | 1.9K | 8.20 | 15K | 329K | SEC |
| 2026-05-26 | 05-28 | Kaiser Peter | Chief Development Officer | S 公開市場賣出(10b5-1) | 3.0K | 8.20 | 24K | 266K | SEC |
| 2026-05-26 | 05-28 | Dugel Pravin | See Remarks | S 公開市場賣出(10b5-1) | 21.2K | 8.20 | 173K | 2.6M | SEC |
| 2026-05-26 | 05-28 | Heier Jeffrey S. | Chief Scientific Officer | S 公開市場賣出(10b5-1) | 3.0K | 8.20 | 25K | 320K | SEC |
| 2026-04-09 | 04-13 | Dugel Pravin | See Remarks | G 贈與 | 395K | – | – | 395K | SEC |
| 2026-04-09 | 04-13 | Dugel Pravin | See Remarks | G 贈與 | 395K | – | – | 2.6M | SEC |
| 2026-02-23 | 02-25 | Kaiser Peter | Chief Development Officer | S 公開市場賣出(10b5-1) | 2.8K | 8.28 | 23K | 269K | SEC |
| 2026-02-23 | 02-25 | Nayak Sanjay | Chief Strategy Officer | S 公開市場賣出(10b5-1) | 1.8K | 8.28 | 15K | 331K | SEC |
| 2026-02-23 | 02-25 | Dugel Pravin | See Remarks | S 公開市場賣出(10b5-1) | 20.1K | 8.28 | 166K | 3.0M | SEC |
| 2026-02-23 | 02-25 | Heier Jeffrey S. | Chief Scientific Officer | S 公開市場賣出(10b5-1) | 3.1K | 8.28 | 25K | 323K | SEC |
| 2026-02-20 | 02-24 | Waheed Nadia | Chief Medical Officer | S 公開市場賣出(10b5-1) | 3.5K | 7.74 | 27K | 315K | SEC |
| 2026-02-20 | 02-24 | LINDSTROM RICHARD L MD | Director | P 公開市場買進 | 60.2K | 7.66 | 461K | 247K | SEC |
| 2026-02-12 | 02-17 | Waheed Nadia | Chief Medical Officer | S 公開市場賣出(10b5-1) | 7.9K | 9.04 | 71K | 318K | SEC |
| 2026-02-12 | 02-17 | Nayak Sanjay | Chief Strategy Officer | S 公開市場賣出(10b5-1) | 10.3K | 9.04 | 94K | 332K | SEC |
| 2026-02-12 | 02-17 | Dugel Pravin | See Remarks | S 公開市場賣出(10b5-1) | 125K | 9.04 | 1.1M | 3.0M | SEC |
| 2026-02-12 | 02-17 | Notman Donald | Chief Operating Officer | S 公開市場賣出 | 11.4K | 9.04 | 103K | 366K | SEC |
| 2026-02-04 | 02-04 | Notman Donald | Chief Operating Officer | S 公開市場賣出 | 6.0K | 8.54 | 52K | 378K | SEC |
| 2026-02-02 | 02-04 | Notman Donald | Chief Operating Officer | S 公開市場賣出 | 5.5K | 9.14 | 50K | 384K | SEC |
| 2026-01-21 | 01-26 | Robinson David Wayne | Global CCO | A 獲配股票 | 136K | – | – | 136K | SEC |
| 2026-01-02 | 01-06 | Nayak Sanjay | Chief Strategy Officer | A 獲配股票 | 64.9K | – | – | 343K | SEC |
| 2026-01-02 | 01-06 | Meyers Steve Lawrence | Chief Commercial Officer | A 獲配股票 | 64.9K | – | – | 218K | SEC |
| 2026-01-02 | 01-06 | Waheed Nadia | Chief Medical Officer | A 獲配股票 | 79.1K | – | – | 326K | SEC |
| 2026-01-02 | 01-06 | Kaiser Peter | Chief Development Officer | A 獲配股票 | 79.1K | – | – | 272K | SEC |
| 2026-01-02 | 01-06 | Saroj Namrata | Chief Business Officer | A 獲配股票 | 79.1K | – | – | 255K | SEC |
| 2026-01-02 | 01-06 | Heier Jeffrey S. | Chief Scientific Officer | A 獲配股票 | 79.1K | – | – | 326K | SEC |
| 2026-01-02 | 01-06 | Notman Donald | See Remarks | A 獲配股票 | 79.1K | – | – | 389K | SEC |
| 2026-01-02 | 01-06 | Anderman Todd | Chief Legal Officer | A 獲配股票 | 64.9K | – | – | 152K | SEC |
| 2025-11-26 | 11-26 | Dugel Pravin | See Remarks | G 贈與 | 49.8K | – | – | 300K | SEC |
| 2025-11-26 | 11-26 | Dugel Pravin | See Remarks | G 贈與 | 49.8K | – | – | 0 | SEC |
| 2025-11-24 | 11-26 | Kaiser Peter | Chief Development Officer | S 公開市場賣出(10b5-1) | 3.0K | 12.02 | 36K | 191K | SEC |
| 2025-11-24 | 11-26 | Nayak Sanjay | Chief Strategy Officer | S 公開市場賣出(10b5-1) | 1.9K | 12.04 | 23K | 278K | SEC |
| 2025-11-24 | 11-26 | Heier Jeffrey S. | Chief Scientific Officer | S 公開市場賣出(10b5-1) | 3.5K | 12.04 | 42K | 246K | SEC |
| 2025-11-24 | 11-26 | Dugel Pravin | See Remarks | S 公開市場賣出(10b5-1) | 19.5K | 12.04 | 235K | 3.2M | SEC |
| 2025-11-05 | 11-07 | Saroj Namrata | Chief Business Officer | S 公開市場賣出(10b5-1) | 25.9K | 10.74 | 278K | 174K | SEC |
| 2025-10-08 | 10-10 | Anderman Todd | Chief Legal Officer | S 公開市場賣出(10b5-1) | 11.1K | 12.34 | 137K | 87.6K | SEC |
| 2025-10-02 | 10-06 | Kaiser Peter | Chief Development Officer | S 公開市場賣出(10b5-1) | 9.7K | 11.03 | 106K | 194K | SEC |
| 2025-10-02 | 10-06 | Heier Jeffrey S. | Chief Scientific Officer | S 公開市場賣出(10b5-1) | 10.5K | 11.04 | 116K | 249K | SEC |
| 2025-09-09 | 09-11 | Dugel Pravin | See Remarks | G 贈與 | 49.8K | – | – | 3.2M | SEC |
| 2025-09-09 | 09-11 | Dugel Pravin | See Remarks | G 贈與 | 49.8K | – | – | 49.8K | SEC |
| 2025-09-02 | 09-04 | Notman Donald | See Remarks | S 公開市場賣出 | 1.1K | 12.43 | 13K | 309K | SEC |
| 2025-08-25 | 08-27 | Kaiser Peter | Chief Development Officer | S 公開市場賣出(10b5-1) | 3.0K | 12.04 | 36K | 204K | SEC |
| 2025-08-25 | 08-27 | Nayak Sanjay | Chief Strategy Officer | S 公開市場賣出(10b5-1) | 1.9K | 12.04 | 23K | 280K | SEC |
| 2025-08-25 | 08-27 | Heier Jeffrey S. | Chief Scientific Officer | S 公開市場賣出(10b5-1) | 3.1K | 12.04 | 37K | 260K | SEC |
| 2025-08-25 | 08-27 | Dugel Pravin | See Remarks | S 公開市場賣出(10b5-1) | 21.5K | 12.04 | 259K | 3.2M | SEC |
| 2025-08-12 | 08-14 | Waheed Nadia | Chief Medical Officer | A 獲配股票 | 40.4K | – | – | 247K | SEC |
| 2025-08-11 | 08-13 | Dugel Pravin | See Remarks | G 贈與 | 250K | – | – | 250K | SEC |
| 2025-06-12 | 08-13 | Dugel Pravin | See Remarks | G 贈與 | 50.0K | – | – | 3.2M | SEC |
| 2025-06-11 | 06-13 | Graves Adrienne L | Director | A 獲配股票 | 14.0K | – | – | 50.0K | SEC |
| 2025-06-11 | 06-13 | Hong Seung Suh | Director | A 獲配股票 | 14.0K | – | – | 46.9K | SEC |
| 2025-06-11 | 06-13 | RAINES MERILEE | Director | A 獲配股票 | 14.0K | – | – | 46.9K | SEC |
| 2025-06-11 | 06-13 | Warden Charles M | Director | A 獲配股票 | 14.0K | – | – | 86.5K | SEC |
| 2025-06-11 | 06-13 | LINDSTROM RICHARD L MD | Director | A 獲配股票 | 14.0K | – | – | 143K | SEC |
| 2025-06-11 | 06-13 | Williams Leslie J. | Director | A 獲配股票 | 14.0K | – | – | 51.4K | SEC |
| 2025-06-02 | 06-03 | Waheed Nadia | Chief Medical Officer | S 公開市場賣出(10b5-1) | 13.9K | 8.05 | 112K | 207K | SEC |
| 2025-05-23 | 05-27 | Nayak Sanjay | Chief Strategy Officer | S 公開市場賣出(10b5-1) | 1.9K | 7.17 | 13K | 282K | SEC |
| 2025-05-23 | 05-27 | Kaiser Peter | Chief Development Officer | S 公開市場賣出(10b5-1) | 3.0K | 7.17 | 21K | 207K | SEC |
| 2025-05-23 | 05-27 | Heier Jeffrey S. | Chief Scientific Officer | S 公開市場賣出(10b5-1) | 3.0K | 7.18 | 22K | 263K | SEC |
| 2025-05-23 | 05-27 | Dugel Pravin | See Remarks | S 公開市場賣出(10b5-1) | 21.2K | 7.18 | 152K | 3.5M | SEC |
| 2025-05-08 | 05-12 | LINDSTROM RICHARD L MD | Director | P 公開市場買進 | 10.0K | 6.96 | 70K | 173K | SEC |
| 2025-04-28 | 08-13 | Dugel Pravin | See Remarks | G 贈與 | 200K | – | – | 3.3M | SEC |
| 2025-02-24 | 02-26 | Nayak Sanjay | Chief Strategy Officer | S 公開市場賣出(10b5-1) | 1.9K | 6.84 | 13K | 283K | SEC |
機構持股(13F) 管理規模 1 億美元以上的機構,每季末後 45 天內申報 · 最新 2026-06-30
前 25 大持有機構季末市值 · 與前一季股數比較
| 機構 | 持股 | 季末市值 | 股數季變化 | 動作 |
|---|---|---|---|---|
| FMR LLC | 32.8M | 323M | 新進 | 新進 |
| Deep Track Capital, LP | 19.7M | 193M | 新進 | 新進 |
| BlackRock, Inc. | 19.4M | 190M | 新進 | 新進 |
| Avoro Capital Advisors LLC | 12.5M | 123M | 新進 | 新進 |
| Summer Road LLC | 12.2M | 120M | 新進 | 新進 |
| Venrock Adviser, LLC | 10.3M | 102M | 新進 | 新進 |
| VANGUARD CAPITAL MANAGEMENT LLC | 8.8M | 86.7M | 新進 | 新進 |
| Logos Global Management LP | 5.3M | 52.0M | 新進 | 新進 |
| STATE STREET CORP | 5.2M | 51.4M | 新進 | 新進 |
| GEODE CAPITAL MANAGEMENT, LLC | 5.0M | 49.3M | 新進 | 新進 |
| Point72(柯恩) Point72 Asset Management, L.P. | 3.3M | 32.3M | 新進 | 新進 |
| DIMENSIONAL FUND ADVISORS LP | 2.8M | 27.3M | 新進 | 新進 |
| DELTEC ASSET MANAGEMENT LLC | 2.5M | 24.3M | 新進 | 新進 |
| Balyasny Asset Management L.P. | 2.3M | 22.3M | 新進 | 新進 |
| Octagon Capital Advisors LP | 2.1M | 20.4M | 新進 | 新進 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2.0M | 19.4M | 新進 | 新進 |
| NORTHERN TRUST CORP | 1.8M | 17.7M | 新進 | 新進 |
| GOLDMAN SACHS GROUP INC | 1.8M | 17.3M | 新進 | 新進 |
| Nuveen, LLC | 1.7M | 16.7M | 新進 | 新進 |
| Woodline Partners LP | 1.7M | 16.4M | 新進 | 新進 |
| TCG Crossover Management, LLC | 1.6M | 16.2M | 新進 | 新進 |
| UBS Group AG | 1.6M | 15.2M | 新進 | 新進 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.6M | 15.2M | 新進 | 新進 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.5M | 15.1M | 新進 | 新進 |
| Defilade Capital Management, L.P. | 1.5M | 14.6M | 新進 | 新進 |
持有機構數近 12 季
每季 13F 申報中持有本股的機構家數;綠柱 = 比上季少。機構數是「有多少人在船上」,不是「買了多少」。
| 持有機構 · 季變化 | 262 -9 |
|---|---|
| 新進 / 出清 / 加碼 / 減碼 | 262 / 0 / 0 / 0 |
| 機構合計持股 · 佔流通股 | 207M · 94.4% |
| 合計季末市值 | 1.9B |
13F 只申報多頭部位(含可轉債與選擇權,選擇權這裡已排除),不申報放空,也不申報 1 億美元以下的機構。同一集團多個申報主體會各算一家。
放空餘額 FINRA 每月兩次(15 日與月底結算)· 最新 2026-08-31
空單佔流通股近 13 個月
FINRA 每月兩次結算的空單餘額佔流通股數的比例,近 13 個月。滑到柱子看股數與回補天數。
最新一期
| 空單股數 | 28.1M |
|---|---|
| 與上期比 | -1.6% |
| 佔流通股數 | 12.77% |
| 日均成交量 | 3.1M |
| 回補天數 | 9.0 天 |
空單佔比 10% 以上算高、20% 以上算很高(這是通行的說法,不是本站的判斷)。回補天數 = 空單 ÷ 日均量,天數愈長,空方要出場時愈容易推升股價。
放空餘額是「有人借股票賣掉還沒還」的存量,不代表看空的人正在加碼;避險基金做多空配對時也會產生空單。
| 結算日 | 空單股數 | 與上期比 | 佔流通股 | 日均量 | 回補天數 |
|---|---|---|---|---|---|
| 2026-08-31 | 28.1M | -1.6% | 12.77% | 3.1M | 9.0 |
| 2026-08-14 | 28.5M | +6.7% | 12.98% | 2.2M | 12.7 |
| 2026-07-31 | 26.7M | -1.1% | 12.17% | 2.0M | 13.5 |
| 2026-07-15 | 27.0M | +1.3% | 12.31% | 2.1M | 13.1 |
| 2026-06-30 | 26.7M | +0.9% | 12.16% | 4.1M | 6.6 |
| 2026-06-15 | 26.5M | +5.5% | 12.05% | 2.2M | 11.9 |
| 2026-05-29 | 25.1M | +1.2% | 11.42% | 2.8M | 9.0 |
| 2026-05-15 | 24.8M | -0.1% | 11.28% | 2.9M | 8.5 |
| 2026-04-30 | 24.8M | +1.1% | 11.29% | 2.9M | 8.6 |
| 2026-04-15 | 24.5M | -2.6% | 11.17% | 3.5M | 7.0 |
| 2026-03-31 | 25.2M | +6.4% | 11.47% | 3.5M | 7.2 |
| 2026-03-13 | 23.7M | +34.2% | 10.78% | 6.7M | 3.6 |
| 2026-02-27 | 17.6M | +20.0% | 8.04% | 12.3M | 1.4 |
| 2026-02-13 | 14.7M | +27.8% | 6.70% | 4.9M | 3.0 |
| 2026-01-30 | 11.5M | -10.0% | 5.24% | 4.3M | 2.7 |
| 2026-01-15 | 12.8M | +3.6% | 5.82% | 5.8M | 2.2 |
| 2025-12-31 | 12.3M | +16.5% | 5.62% | 2.9M | 4.3 |
| 2025-12-15 | 10.6M | -8.9% | 4.82% | 4.5M | 2.3 |
| 2025-11-28 | 11.6M | -11.7% | 5.30% | 3.1M | 3.8 |
| 2025-11-14 | 13.2M | -4.4% | 6.00% | 1.9M | 6.9 |
| 2025-10-31 | 13.8M | +1.4% | 6.27% | 2.1M | 6.5 |
| 2025-10-15 | 13.6M | +0.2% | 6.19% | 4.5M | 3.1 |
| 2025-09-30 | 13.6M | -11.3% | 6.17% | 2.7M | 5.0 |
| 2025-09-15 | 15.3M | +10.4% | 6.96% | 2.7M | 5.6 |
| 2025-08-29 | 13.8M | +5.8% | 6.30% | 1.7M | 8.1 |
| 2025-08-15 | 13.1M | +1.9% | 5.96% | 2.3M | 5.6 |